Mayank Mamtani
Stock Analyst at B. Riley Securities
(4.41)
# 379
Out of 4,761 analysts
119
Total ratings
41.9%
Success rate
34.93%
Average return
Main Sectors:
Stocks Rated by Mayank Mamtani
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VKTX Viking Therapeutics | Reiterates: Buy | $109 → $96 | $34.07 | +181.77% | 2 | Feb 7, 2025 | |
| NKTR Nektar Therapeutics | Initiates: Buy | $4 | $0.93 | +329.09% | 1 | Jan 8, 2025 | |
| CGTX Cognition Therapeutics | Upgrades: Buy | $1 → $1.5 | $0.58 | +157.20% | 3 | Dec 19, 2024 | |
| MDGL Madrigal Pharmaceuticals | Maintains: Neutral | $194 → $236 | $336.23 | -29.81% | 11 | Nov 5, 2024 | |
| NVAX Novavax | Reiterates: Buy | $23 → $26 | $7.99 | +225.41% | 19 | Oct 10, 2024 | |
| TRVI Trevi Therapeutics | Reiterates: Buy | $6 | $4.60 | +30.43% | 2 | Oct 7, 2024 | |
| CNTA Centessa Pharmaceuticals | Initiates: Buy | $33 | $16.63 | +98.44% | 1 | Sep 19, 2024 | |
| HROW Harrow | Reiterates: Buy | $50 | $28.95 | +72.71% | 1 | Aug 29, 2024 | |
| ALT Altimmune | Reiterates: Buy | $20 | $6.43 | +211.04% | 9 | Aug 12, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Buy | $55 | $19.90 | +176.38% | 6 | Aug 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $34 | $30.88 | +10.10% | 13 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $18 → $5 | $2.76 | +81.16% | 1 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $122 → $92 | $50.26 | +83.05% | 3 | Jun 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 | $0.71 | +180.31% | 5 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $3.13 | +27.80% | 3 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $0.33 | +1,112.86% | 1 | Oct 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $38 | $20.73 | +83.31% | 1 | Sep 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $3 | $0.47 | +542.26% | 5 | Apr 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $160 | $3.32 | +4,719.28% | 1 | Mar 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $5 | $2.27 | +120.26% | 3 | Aug 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $58 → $44 | $2.55 | +1,625.49% | 4 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $90 | $1.62 | +5,455.56% | 4 | Jul 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $4 | $0.68 | +491.72% | 1 | Jun 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 → $7 | $8.59 | -18.51% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9,750 → $4,500 | $2.95 | +152,442.37% | 3 | Jan 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $500 → $270 | $1.48 | +18,143.24% | 2 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $138 → $77 | $17.77 | +333.31% | 2 | Jan 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1,980 → $1,440 | $2.70 | +53,172.17% | 3 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.49 | +168.46% | 2 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $47 → $39 | $96.84 | -59.73% | 2 | Mar 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $11 | $1.83 | +501.09% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $34 | $3.83 | +787.73% | 1 | Mar 13, 2020 |
Viking Therapeutics
Feb 7, 2025
Reiterates: Buy
Price Target: $109 → $96
Current: $34.07
Upside: +181.77%
Nektar Therapeutics
Jan 8, 2025
Initiates: Buy
Price Target: $4
Current: $0.93
Upside: +329.09%
Cognition Therapeutics
Dec 19, 2024
Upgrades: Buy
Price Target: $1 → $1.5
Current: $0.58
Upside: +157.20%
Madrigal Pharmaceuticals
Nov 5, 2024
Maintains: Neutral
Price Target: $194 → $236
Current: $336.23
Upside: -29.81%
Novavax
Oct 10, 2024
Reiterates: Buy
Price Target: $23 → $26
Current: $7.99
Upside: +225.41%
Trevi Therapeutics
Oct 7, 2024
Reiterates: Buy
Price Target: $6
Current: $4.60
Upside: +30.43%
Centessa Pharmaceuticals
Sep 19, 2024
Initiates: Buy
Price Target: $33
Current: $16.63
Upside: +98.44%
Harrow
Aug 29, 2024
Reiterates: Buy
Price Target: $50
Current: $28.95
Upside: +72.71%
Altimmune
Aug 12, 2024
Reiterates: Buy
Price Target: $20
Current: $6.43
Upside: +211.04%
Arrowhead Pharmaceuticals
Aug 12, 2024
Reiterates: Buy
Price Target: $55
Current: $19.90
Upside: +176.38%
Aug 7, 2024
Maintains: Buy
Price Target: $29 → $34
Current: $30.88
Upside: +10.10%
Jul 31, 2024
Downgrades: Neutral
Price Target: $18 → $5
Current: $2.76
Upside: +81.16%
Jun 4, 2024
Maintains: Buy
Price Target: $122 → $92
Current: $50.26
Upside: +83.05%
Jan 31, 2024
Upgrades: Buy
Price Target: $2
Current: $0.71
Upside: +180.31%
Dec 20, 2023
Maintains: Buy
Price Target: $8 → $4
Current: $3.13
Upside: +27.80%
Oct 13, 2023
Initiates: Buy
Price Target: $4
Current: $0.33
Upside: +1,112.86%
Sep 6, 2023
Initiates: Buy
Price Target: $38
Current: $20.73
Upside: +83.31%
Apr 10, 2023
Maintains: Buy
Price Target: $7 → $3
Current: $0.47
Upside: +542.26%
Mar 29, 2023
Reiterates: Buy
Price Target: $160
Current: $3.32
Upside: +4,719.28%
Aug 19, 2022
Downgrades: Neutral
Price Target: $11 → $5
Current: $2.27
Upside: +120.26%
Aug 11, 2022
Maintains: Buy
Price Target: $58 → $44
Current: $2.55
Upside: +1,625.49%
Jul 14, 2022
Maintains: Buy
Price Target: $120 → $90
Current: $1.62
Upside: +5,455.56%
Jun 14, 2022
Initiates: Buy
Price Target: $4
Current: $0.68
Upside: +491.72%
May 24, 2022
Downgrades: Neutral
Price Target: $14 → $7
Current: $8.59
Upside: -18.51%
Jan 24, 2022
Maintains: Buy
Price Target: $9,750 → $4,500
Current: $2.95
Upside: +152,442.37%
Nov 30, 2021
Maintains: Buy
Price Target: $500 → $270
Current: $1.48
Upside: +18,143.24%
Jan 15, 2021
Downgrades: Neutral
Price Target: $138 → $77
Current: $17.77
Upside: +333.31%
May 22, 2020
Downgrades: Neutral
Price Target: $1,980 → $1,440
Current: $2.70
Upside: +53,172.17%
Apr 3, 2020
Maintains: Buy
Price Target: $8 → $4
Current: $1.49
Upside: +168.46%
Mar 18, 2020
Maintains: Buy
Price Target: $47 → $39
Current: $96.84
Upside: -59.73%
Mar 13, 2020
Maintains: Buy
Price Target: $22 → $11
Current: $1.83
Upside: +501.09%
Mar 13, 2020
Maintains: Buy
Price Target: $43 → $34
Current: $3.83
Upside: +787.73%